公开(公告)号：US20240316100A1

公开(公告)日：2024-09-26

申请号：US18270261

申请日：2021-12-29

Applicant: INTELLIA THERAPEUTICS, INC.

Inventor： Christopher RUDULIER

IPC: A61K35/17 ,  A61K39/00 ,  A61P37/06 ,  C12N5/0783 ,  C12N5/10

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4621 ,  A61K39/4631 ,  A61K39/46433 ,  A61K39/46434 ,  A61K39/464466 ,  A61P37/06 ,  C12N5/0636 ,  C12N5/10 ,  C12N2510/00

Abstract: The present disclosure relates to T cells engineered to comprise a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding an IFNG, a modification, e.g., knockdown, of an endogenous nucleic acid sequence encoding a TNFA, and insertion of sequence(s) encoding a regulatory T cell promoting molecule and compositions and uses thereof.